Krebs Biochemicals and Industries Limited
NSE: KREBSBIO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Krebs Biochemicals and Industries Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Krebs Biochemicals & Industries Ltd is an Indian pharmaceutical company established in 1991 that specialises in the manufacturing of active pharmaceutical ingredients (APIs). Its current product portfolio includes steroid intermediates and anti-cholesterol medications.
Business Model
The company generates revenue through the large-scale production and sale of active pharmaceutical ingredients to the healthcare and pharmaceutical sectors. It focuses on both established steroid intermediates and cholesterol-management drugs.
- Incorporation Year:1991
Growth Outlook
Growth is expected to be driven by the commercialisation of upcoming products, including Amlodipine, Cetirizine, Orlistat, Telmisartan, Serratiopepetidase, and Phenylephrine.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety standards set by pharmaceutical regulatory bodies, where non-compliance could lead to production halts.
- Market Competition. The API manufacturing sector is highly competitive, potentially impacting profit margins due to pricing pressures from domestic and international peers.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact the company's operating costs and profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Krebs Biochemicals and Industries Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹24 Cr
TTM · standalone
NET PROFIT
₹-17 Cr
TTM · standalone
EPS
₹-7.86
TTM · standalone
RETURN ON EQUITY
11.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
-16.0%
TTM · standalone
P/E
-8.7x
Q4 FY26 · standalone
EV/EBITDA
-101.7x
Q4 FY26 · standalone
EBITDA MARGIN
-14.5%
TTM · standalone
NET PROFIT MARGIN
-34.4%
Q4 FY26 · standalone
DEBT TO EQUITY
-1.4x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Krebs Biochemicals and Industries LimitedKREBSBIO | ₹124 Cr | -8.66 | -101.68 | -45.2% | -14.5% | 11.3% | -16.0% | -4.6% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Q4 FY26
Financials
Krebs Biochemicals and Industries Limited
NSE: KREBSBIO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Krebs Biochemicals and Industries Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Krebs Biochemicals & Industries Ltd is an Indian pharmaceutical company established in 1991 that specialises in the manufacturing of active pharmaceutical ingredients (APIs). Its current product portfolio includes steroid intermediates and anti-cholesterol medications.
Business Model
The company generates revenue through the large-scale production and sale of active pharmaceutical ingredients to the healthcare and pharmaceutical sectors. It focuses on both established steroid intermediates and cholesterol-management drugs.
- Incorporation Year:1991
Growth Outlook
Growth is expected to be driven by the commercialisation of upcoming products, including Amlodipine, Cetirizine, Orlistat, Telmisartan, Serratiopepetidase, and Phenylephrine.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety standards set by pharmaceutical regulatory bodies, where non-compliance could lead to production halts.
- Market Competition. The API manufacturing sector is highly competitive, potentially impacting profit margins due to pricing pressures from domestic and international peers.
- Raw Material Price Volatility. Fluctuations in the cost of chemical precursors and raw materials can significantly impact the company's operating costs and profitability.
Start your research today
Unlock AI insights, financials, peers and live data on Krebs Biochemicals and Industries Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹24 Cr
TTM · standalone
NET PROFIT
₹-17 Cr
TTM · standalone
EPS
₹-7.86
TTM · standalone
RETURN ON EQUITY
11.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
-16.0%
TTM · standalone
P/E
-8.7x
Q4 FY26 · standalone
EV/EBITDA
-101.7x
Q4 FY26 · standalone
EBITDA MARGIN
-14.5%
TTM · standalone
NET PROFIT MARGIN
-34.4%
Q4 FY26 · standalone
DEBT TO EQUITY
-1.4x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26